Business Context and Reporting Period
Company: MICROVISION, INC.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: March 31, 1999
Business Overview: Microvision is a development-stage company focused on commercializing Virtual Retinal Display (VRD) technology. The company generates revenue primarily through development contracts with government and commercial entities while incurring significant operating losses to fund research, prototype development, and the expansion of in-house laboratories.
Key Financial Metrics
| Metric | Q1 1999 | Q1 1998 |
|---|---|---|
| Contract Revenue | $2,301,600 | $1,708,200 |
| Gross Margin | $592,000 (25.7%) | $568,400 (33.3%) |
| Net Loss | $(2,002,000) | $(1,216,500) |
| Net Loss Available to Common Shareholders | $(3,150,000) | $(1,216,500) |
| Loss Per Share (Basic & Diluted) | $(0.51) | $(0.20) |
| Cash and Cash Equivalents (End of Period) | $3,946,500 | $2,698,500 |
| Total Assets | $9,238,600 | $6,362,200 |
| Total Liabilities | $3,286,300 | $3,773,200 |
| Accumulated Deficit | $(25,986,000) | $(22,836,000) |
Liquidity: As of March 31, 1999, the company held $4.45 million in total cash, cash equivalents, and investment securities. The company has no bank line of credit but utilizes a non-recourse receivables assignment facility with a $2.5 million limit.
Material Changes vs. Prior Period
- Revenue Growth: Contract revenue increased 35% to $2.3 million, driven by higher recognition of revenue from development contracts entered into in 1998 and 1999.
- Expense Increases:
- Cost of Revenue: Increased 50% to $1.7 million due to higher direct/indirect contract costs and increased investment in technical capabilities.
- R&D Expense: Increased 23% to $881,800 to support staff expansion and laboratory equipment.
- SG&A Expense: Increased 47% to $1.7 million, primarily due to higher compensation for sales, marketing, and management staff.
- Non-Cash Charge: A significant non-cash charge of $1.148 million was recorded for the beneficial conversion feature of Series B Preferred Stock issued in January 1999, increasing the net loss available to common shareholders.
- Cash Flow: Net cash used in operating activities increased to $2.5 million (from $2.2 million in Q1 1998). However, financing activities provided $5.2 million, primarily from the sale of preferred and common stock, resulting in a net cash increase of $1.7 million for the quarter.
Guidance, Outlook, and Risks
Management Commentary & Outlook:
- The company expects to continue incurring significant operating losses over the next several years as it funds prototype development and commercialization efforts.
- Cost of revenue is expected to increase in absolute dollars but decline as a percentage of revenue due to anticipated economies of scale.
- Management believes current cash balances ($4.5 million) plus $7.9 million in proceeds received subsequent to March 31, 1999, will satisfy budgeted requirements for at least the next 12 months.
Subsequent Events (Post-March 31, 1999):
- April 1999: Raised $6.0 million via private placement of common stock.
- May 1999: Raised $4.5 million from Cree Research, Inc. and entered into a $2.6 million one-year development contract with Cree.
Risks and Contingencies:
- Liquidity Risk: Future capital requirements depend on R&D progress and market acceptance. If additional financing is not available, operations may need to be limited.
- Lease Obligations: The company relocated to a new headquarters in April 1999 under a triple-net lease requiring a $1.15 million lease bond (secured by cash/letters of credit).
- Year 2000 (Y2K) Compliance: The company is implementing a compliance strategy. While costs to date are immaterial, a failure in internal or third-party systems could materially disrupt operations.
- Contract Losses: An allowance for estimated contract losses of $360,000 was recorded on the balance sheet.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $12.4 million total liquidity (cash on hand + subsequent proceeds) against the projected burn rate for the full year 1999.
- Revenue Quality: Assess the concentration of revenue among specific development contracts and the likelihood of renewal or conversion to commercial product sales.
- Dilution Impact: Review the terms of the Series B Preferred Stock and subsequent common stock issuances to understand the dilution effect on existing shareholders.
- Lease Commitments: Confirm the impact of the new headquarters lease and the $1.15 million bond requirement on future cash flows.
- Y2K Exposure: Evaluate the status of the Y2K compliance assessment and the potential operational impact of third-party vendor failures.